MiMedx Launches Thickest Placental Allograft for Complex Wounds
Event summary
- MiMedx launched CHORIOFIX™, its thickest placental allograft to date, on March 23, 2026.
- The product features two chorion layers with an intact intermediate layer, designed for large and deep wounds.
- CHORIOFIX has been added to the CAMPAIGN trial, a prospective RCT comparing it to standard of care for diabetic foot ulcers.
- Early clinical feedback highlights improved handling and effective wound closure in complex cases.
The big picture
MiMedx's launch of CHORIOFIX reinforces its focus on placental allograft innovation, targeting the growing demand for solutions in chronic and complex wound care. The addition of the product to its CAMPAIGN trial underscores the company's strategy of leveraging clinical data to drive market adoption. In an industry where reimbursement and efficacy are critical, MiMedx is positioning itself as a leader in advanced wound healing technologies.
What we're watching
- Clinical Validation
- How CHORIOFIX performs in the CAMPAIGN trial will determine its long-term market positioning.
- Competitive Differentiation
- Whether MiMedx can sustain its lead in advanced wound care with this thicker allograft design.
- Adoption Pace
- The speed at which hospitals and clinicians integrate CHORIOFIX into treatment protocols for complex wounds.